| Literature DB >> 35784100 |
E Glover1, A Abrahamson2, J Adams2, S R Poken2, S-L Hainsworth2, A Lamprecht2, T Delport2, T Keulder2, T Olivier2, S D Maasdorp3.
Abstract
Background: Central line-associated bloodstream infections (CLABSIs) are frequently encountered device-related healthcare-associated infections in critically ill patients, causing substantial morbidity, mortality and prolonged hospitalisation.Entities:
Keywords: central line-associated bloodstream infections; intensive care; line days
Year: 2022 PMID: 35784100 PMCID: PMC9235866 DOI: 10.7196/AJTCCM.2022.v28i1.175
Source DB: PubMed Journal: Afr J Thorac Crit Care Med ISSN: 2617-0191
General characteristics of the study population who developed CLABSIs
|
|
|
|
| |
| Male | 23 (76.7) |
| Female | 7 (23.3) |
|
| |
| Medical | 14 (46.7) |
| Surgery | 5 (16.7) |
| Neurosurgery | 8 (26.7) |
| Gynaecology | 2 (6.7) |
| Other | 1 (3.3) |
|
| |
| <3 days | 5 (15.6) |
| 3 - 8 days | 22 (68.8) |
| >8 days | 5 (15.6) |
|
| |
| MICU | 13 (43.3) |
| Theatre | 11 (36.7) |
| Ward | 6 (20.0) |
|
| |
| Pneumonia | 11 (36.7) |
| Urinary tract infection | 3 (10.0) |
| Meningitis | 1 (3.3) |
| Abdominal disease | 1 (3.3) |
| Unknown | 14 (46.7) |
|
| 29 (96.7) |
|
| 14 (46.7) |
CLABSI = central line-associated bloodstream infection
MICU = multidisciplinary intensive care unit
Microorganisms cultured (n=38) from 30 patients with CLABSI
|
|
|
|
| 15 (39.5) |
| | 7 (18.4) |
| | 7 (18.4) |
| | 1 (2.6) |
|
| 21 (55.3) |
| | 6 (15.8) |
| | 12 (31.6) |
| | 1 (2.6) |
| | 1 (2.6) |
| | 1 (2.6) |
|
| |
| | 2 (5.3) |
CLABSI = central line-associated bloodstream infection
Susceptibility profile of microorganisms
|
| ||||||||
|
| ||||||||
| Amikacin | - | - | - | 1 (8.3) | 1 (100.0) | 6 (100.0) | 1 (100.0) | |
| Gentamycin | - | - | - | - | - | - | - | - |
| Ampicillin | 4 (57.1) | 7 (100.0) | 0 | - | 0 | - | 0 | 0 |
| Amoxicillin-clavulanic acid | - | - | - | - | - | 2 (33.3) | 0 | 0 |
| Cefepime | - | - | - | - | 1 (100.0) | 2 (33.3) | 1 (100.0) | 1 (100.0) |
| Cefuroxime | - | - | - | - | - | 2 (33.3) | 1 (100.0) | 0 |
| Cefotaxime | - | - | - | - | 0 | 2 (33.3) | 1 (100.0) | 0 |
| Cefoxitin | - | - | - | - | 0 | 2 (33.3) | 1 (100.0) | - |
| Ceftazidime | - | - | - | 1 (100.0) | 2 (33.3) | 1 (100.0) | 0 | |
| Ciprofloxacin | - | 5 (71.4) | 0 | 0 | 1 (100.0) | 3 (50.0) | 1 (100.0) | |
| Clindamycin | 4 (57.1) | |||||||
| Cloxacillin | 4 (57.1) | - | - | - | - | - | - | |
| Ertapenem | - | - | - | 0 | - | 4 (66.7) | 1 (100.0) | 1 (100.0) |
| Erythromycin | 4 (57.1) | 0 | 0 | - | - | - | - | - |
| Imipenem | - | - | - | 0 (0) | 1 (100.0) | 4 (66.7) | 1 (100.0) | 1 (100.0) |
| Linezolid | 7 (100.0) | 7 (100.0) | 1 (100.0) | - | - | - | - | - |
| Meropenem | - | - | - | 0 | 1 (100.0) | 4 (66.7) | 1 (100.0) | 1 (100.0) |
| Piperacillin-tazobactam | - | - | - | 0 | 1 (100.0) | 2 (33.3) | 1 (100.0) | - |
| Trimethoprim-sulfamethoxazole | 6 (85.7) | - | - | - | - | - | 0 | 1 (100.0) |
| Vancomycin | 7 (100.0) | 7 (100.0) | 0 | - | - | - | - | |
| Tigecycline | - | - | - | 10 (83.3) | - | 5 (83.3) | - | 0 |
| Rifampin | 5 (71.4) | - | - | - | - | - | - | - |
S.aureus = Staphylococcus aureus
E.faecalis = Enterococcus faecalis
E.faecium = Enterococcus faecium
A.baumanii = Acinetobacter baumanii
P.aeruginosa = Pseudomonas aeruginosa
K.pneumoniae = Klebsiella pneumoniae
P.stuartii = Providencia stuartii
* n=2 Klebsiella pneumoniae organisms were extended spectrum b-lactamase strains and n=2 were carbapenem-resistant OXA-48 strains.
† Providencia was an Amp-C strain.